Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages

  Ono, Akira ^a   Takahashi, Toshiaki ^a   Oishi, Takuma ^a   Sugino, Takashi ^a   Akamatsu, Hiroaki ^a   Shukuya, Takehito ^a   Taira, Tetsuhiko ^a   Kenmotsu, Hirotsugu ^a   Naito, Tateaki ^a   Murakami, Haruyasu ^a   Nakajima, Takashi ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CRIZOTINIB; DOCETAXEL; LANSOPRAZOLE; MAGNESIUM OXIDE; METHYLPREDNISOLONE; PEMETREXED; PREDNISOLONE; SIVELESTAT; THIAMAZOLE; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTERIAL OXYGEN TENSION; ARTICLE; AUTOPSY; BLOOD CELL COUNT; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHINODERM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FIBEROPTIC BRONCHOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENERAL CONDITION IMPROVEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG INFILTRATE; LYMPH NODE DISSECTION; MALE; MECHANICAL VENTILATOR; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RESPIRATORY ACIDOSIS; SMOKING; THORAX RADIOGRAPHY; TUMOR RECURRENCE; ADENOCARCINOMA; ADVERSE DRUG REACTION; BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FATALITY; LUNG ALVEOLUS; LUNG TUMOR; PATHOLOGY; CHEMICALLY INDUCED; DRUG EFFECTS; HEMORRHAGE; LUNG NEOPLASMS;

ACUTE LUNG INJURY; ADENOCARCINOMA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATAL OUTCOME; HEMORRHAGE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PULMONARY ALVEOLI; PYRAZOLES; PYRIDINES;

EID: 84891546616     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1110     Document Type: Article

References (18)

1. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010.
2. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012.
3. Kim D-W, Ahn M-J, Shi Y, et al: Results of a global phase II study with crizotinib in advanced ALK-positive non-small-cell lung cancer (NSCLC). J Clin Oncol 30:15, 2012 (suppl; abstr 7533).
4. Rosenow EC 3rd, Limper AH: Drug-induced pulmonary disease. Semin Respir Infect 10:86-95, 1995.
5. Mü ller NL, White DA, Jiang H, et al: Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 91:S24-S30, 2004. (Pubitemid 39334844)
6. Myers JL, Limper AH, Swensen SJ: Drug-induced lung disease: A pragmatic classification incorporating HRCT appearances. Semin Respir Crit Care Med 24:445-454, 2003.
7. Inoue A, Saijo Y, Maemondo M, et al: Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139, 2003. (Pubitemid 36092019)
8. Okamoto I, Fujii K, Matsumoto M, et al: Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40:339-342, 2003. (Pubitemid 36627715)
9. Ieki R, Saitoh E, Shibuya M: Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 22:179-181, 2003. (Pubitemid 36896489)
10. Ando M, Okamoto I, Yamamoto N, et al: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549-2556, 2006. (Pubitemid 46630633)
11. Higenbottam T, Kuwano K, Nemery B, et al: Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 91:S31-S37, 2004. (Pubitemid 39331429)
12. Travis WD, Colby TV, Lombard C, et al: A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 14:1112-1125, 1990.
13. Collard HR, Schwarz MI: Diffuse alveolar hemorrhage. Clin Chest Med 25:583-592, 2004. (Pubitemid 39149804)
14. Jin SM, Yim JJ, Yoo CG, et al: Aetiologies and outcomes of diffuse alveolar haemorrhage presenting as acute respiratory failure of uncertain cause. Respirology 14:290-294, 2009.
15. Green RJ, Ruoss SJ, Kraft SA, et al: Pulmonary capillaritis and alveolar hemorrhage: Update on diagnosis and management. Chest 110:1305-1316, 1996. (Pubitemid 26380491)
16. Christensen JG, Zou HY, Arango ME, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314-3322, 2007.
17. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012.
18. Xalkori (crizotinib, package insert). New York, NY, Pfizer, 2011.